Literature DB >> 19835669

Reduced peripheral brain-derived neurotrophic factor mRNA levels are normalized by antidepressant treatment.

Annamaria Cattaneo1, Luisella Bocchio-Chiavetto, Roberta Zanardini, Elena Milanesi, Anna Placentino, Massimo Gennarelli.   

Abstract

Consistent data coming from biochemical studies have evidenced a brain-derived neurotrophic factor (BDNF) serum reduction in depressed patients compared to controls and a restoration following antidepressant treatment. However, to date, no study has evaluated whether BDNF synthesis in leukocytes could contribute to such modulation. Therefore, in this study, we analysed BDNF mRNA levels in leukocytes from 21 depressed patients prior to and during escitalopram treatment and from 23 control subjects showing that BDNF mRNA levels were decreased in drug-free depressed patients and that 12 wk escitalopram treatment was able to reverse this deficit. Interestingly, changes in BDNF mRNA levels paralleled BDNF serum increase during antidepressant treatment, and were correlated with symptoms improvement. Our results indicate that BDNF serum modulation observed in depressed patients is associated with BDNF synthesis alteration in leukocytes and suggest that these peripheral cells might play an active role in the mechanisms of action of antidepressants.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19835669     DOI: 10.1017/S1461145709990812

Source DB:  PubMed          Journal:  Int J Neuropsychopharmacol        ISSN: 1461-1457            Impact factor:   5.176


  36 in total

Review 1.  [The development of depression: the role of brain-derived neurotrophic factor].

Authors:  H Stuke; R Hellweg; F Bermpohl
Journal:  Nervenarzt       Date:  2012-07       Impact factor: 1.214

Review 2.  Escitalopram: in the treatment of major depressive disorder in adolescent patients.

Authors:  Lily P H Yang; Lesley J Scott
Journal:  Paediatr Drugs       Date:  2010-06       Impact factor: 3.022

Review 3.  Neurotrophin strategies for neuroprotection: are they sufficient?

Authors:  Joseph P Steiner; Avindra Nath
Journal:  J Neuroimmune Pharmacol       Date:  2014-03-08       Impact factor: 4.147

4.  A Load to Find Clinically Useful Biomarkers for Depression.

Authors:  Matea Nikolac Perkovic; Marina Sagud; Lucija Tudor; Marcela Konjevod; Dubravka Svob Strac; Nela Pivac
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 5.  Escitalopram: a review of its use in the management of major depressive disorder in adults.

Authors:  Karly P Garnock-Jones; Paul L McCormack
Journal:  CNS Drugs       Date:  2010-09       Impact factor: 5.749

6.  The expression of VGF is reduced in leukocytes of depressed patients and it is restored by effective antidepressant treatment.

Authors:  Annamaria Cattaneo; Antonella Sesta; Francesca Calabrese; Gabriela Nielsen; Marco Andrea Riva; Massimo Gennarelli
Journal:  Neuropsychopharmacology       Date:  2010-03-17       Impact factor: 7.853

Review 7.  Blood-based biomarkers predicting response to antidepressants.

Authors:  Yasmin Busch; Andreas Menke
Journal:  J Neural Transm (Vienna)       Date:  2018-01-27       Impact factor: 3.575

8.  Brain-derived neurotrophic factor serum levels and genotype: association with depression during interferon-α treatment.

Authors:  Francis E Lotrich; Salwa Albusaysi; Robert E Ferrell
Journal:  Neuropsychopharmacology       Date:  2012-12-18       Impact factor: 7.853

Review 9.  Effect of Exercise on Major Depressive Disorder and Schizophrenia: A BDNF Focused Approach.

Authors:  Evrim Gökçe; Emel Güneş; Erhan Nalçaci
Journal:  Noro Psikiyatr Ars       Date:  2019-10-15       Impact factor: 1.339

10.  Effect of intraoperative application of ketamine on postoperative depressed mood in patients undergoing elective orthopedic surgery.

Authors:  Min Jiang; Mao-Hua Wang; Xiao-Bin Wang; Li Liu; Jia-Li Wu; Xiao-Lin Yang; Xue-Ru Liu; Chun-Xiang Zhang
Journal:  J Anesth       Date:  2015-11-18       Impact factor: 2.078

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.